ScanGrants - Diabetes

Ernest Mario School of Pharmacy 2015 Summer Undergraduate Research Fellowship Program

Ernest Mario School of Pharmacy 2015 Summer Undergraduate Research Fellowship Program

Ernest Mario School of Pharmacy - Rutgers University

The Ernest Mario School of Pharmacy announces the 2015 Summer Undergraduate Research Fellowship (SURF) Program. The program is intended for highly motivated undergraduates interested in a research career in the pharmaceutical and environmental sciences. Students are provided with an opportunity to conduct full-time research in areas related to Pharmacology and Toxicology, Environmental Health Sciences, Pharmaceutics, Medicinal Chemistry, Chemical Biology, and Clinical Pharmacy. The SURF program is open to undergraduate students currently enrolled at a university in the United States. Previous experience performing independent laboratory or clinical research is not required.

The 10-week program will run May 26 through July 31, 2015 and provides a $2,800 stipend. Students must be available for the entire 10-week period. Training includes hands-on research conducted in the laboratories or clinical practices of faculty members, round table discussions of research progress, and seminars on research careers and activities of the faculty. Students also participate in career development workshops and a field trip to a pharmaceutical company. At the end of the fellowship, each student will provide a brief oral presentation on his or her summer research project.

To apply to the Summer Research Fellowship Program:

Complete the online application. You will need to upload a personal statement, CV/resume, and transcripts.

Applications must be submitted online. Your letter of recommendation should be emailed directly to surf@eohsi.rutgers.edu. All application materials must be received by February 5, 2015.  You will receive email notification when we have received your online application and letter of recommendation. Only complete applications will be reviewed.

Students are responsible for finding local housing for the 10-week duration of the SURF program. Additional funding for room and board is not available. All questions concerning summer housing should be directed to the Residence Life Assignments Office at oncampus@rci.rutgers.edu or (848) 445-0750.

For further information, please contact surf@eohsi.rutgers.edu. Students selected for the program will begin to be notified on March 14, 2015. Students will have 1 week to inform the Program of their intent to participate. Notifications of selected students will be made through April 4, 2015. Students who are not selected will be notified by April 11, 2015.  Students selected for SURF are expected to become undergraduate members of the Society of Toxicology and the American Society of Pharmacology and Experimental Therapeutics at no charge and join the SURF LinkedIn Page.

Note: Pharmacy students selected for the SURF program will be placed into Cycle III for their introductory pharmacy practice experience.

The SURF Program at the Ernest Mario School of Pharmacy is financially supported by the National Institute of Environmental Health Sciences (1R25ES020721), the American Society for Pharmacology and Experimental Therapeutics, the Society of Toxicology, the Graduate School of Biomedical Sciences, and the Dean of the School of Pharmacy.

General Research Areas

Pharmacology, Toxicology and Environmental Health Sciences: neurotoxicology; immunology; inflammatory mechanisms of tissue injury; kidney injury; role of extracellular matrix in development and disease pathology; wound healing; nitric oxide biology; pulmonary toxicology, developmental toxicology; environmental health sciences; clinical toxicology

Medicinal Chemistry: design and synthesis of enzyme inhibitors and prodrugs; synthetic organic chemistry, structure activity relationships, medicinal chemistry

Pharmaceutics: design, development and evaluation of drug delivery systems; biopharmaceutics (drug formulation, drug transport); pharmacokinetics

Chemical Biology: cancer biology and prevention; regulation of tumor cell growth and differentiation

Pharmacy Practice: clinical studies; diabetes, seizure disorders, hypertension, geriatric pharmacotherapy and medication therapy management

Orthopaedic Trauma Association Research Grant Program

Orthopaedic Trauma Association Research Grant Program

Pre-proposal Deadline: February 16, 2015.

2015 Grant Awards (Funding begins January 1, 2016)

You may apply in more than one category if applicable.

The following grants are available for any research issue related to musculoskeletal trauma (excluding product development)

Clinical Research Grants ($40,000/year maximum for up to 2 years)

Basic Research Grants ($25,000/year maximum for up to 2 years)

Directed topic research grants:

Clinical studies ($50,000/year maximum for up to 3 years) in the following areas:

Economic Impact of Obesity and Diabetes

Proximal Humerus Fractures

Effectiveness of Systemic Therapies on Healing in Systemically Impaired Patients

Pre-proposal Grading: Pre-proposals will be reviewed and graded in a blinded fashion by members of the OTA Research Committee for anticipated scientific merit, anticipated long-term impact on Orthopaedic Trauma care and general topic interest. Applicants will be notified of status by April 30, 2015.

Full Grant Applications: The authors of those pre-proposals with high scores in the above categories will be invited to submit a standard OTA Grant Application to be received by the OTA office no later than June 15, 2015. The full grant application will be reviewed in an unblinded fashion by an assigned review team and will be scored. The Research Committee will then meet prior to the OTA Annual Meeting to review all of the grant applications and will provide a final rank listing with funding suggestions to the OTA Board.

Researchers will be informed of the intent to fund or not fund their research project by November 30, 2015.

Epilepsy Foundation Targeted Research Initiative for Morbidity and Mortality Grant Program

Epilepsy Foundation Targeted Research Initiative for Morbidity and Mortality Grant Program

Application Deadline: March 20, 2015, 11:59 PM ET

Award Amount: up to $50,000 maximum for one year

Apply via Proposal Central website

Proposal Central website tip: filter the list to show Epilepsy Foundation programs

The Targeted Research Initiative for Morbidity and Mortality supports research that generates initial data leading to more extensive projects that will generate knowledge that will ultimately improve the lives of persons with epilepsy. This initiative recognizes the need for research and new insights into these scientific areas.The broad focus of the morbidity portion of this program includes: identification of somatic comorbidities in epilepsy that occur more than expected among controls, including but not limited to diabetes, gastrointestinal bleeding, chronic lung disease, congenital cardiac abnormalities, heart failure, and pneumonia; and associations between somatic comorbidities in epilepsy and epilepsy outcomes, including quality of life in epilepsy, seizure remission, stigma and other outcomes. The mortality portion of the program is focused upon potentially preventable causes of death in epilepsy, such as accidents, suicide and SUDEP. Applicants are encouraged to examine risk factors for these causes of death in epilepsy; as well as interventions to decrease the presence of risk factors for these causes of death where risk factors have been identified.

The JDRF and the Helmsley Charitable Trust Request Expressions of Interest for Improved Assays for Predicting Risk for T1D

The JDRF and the Helmsley Charitable Trust Request Expressions of Interest for Improved Assays for Predicting Risk for T1D

JDRF and The Leona M. and Harry B. Helmlsey Charitable Trust are soliciting expressions of interest (EOI) for optimizing and validating existing technologies for predictive screening for T1D risk and autoimmunity to be applied for wide-spread use in population-based screening efforts, including newborn or childhood based screening. EOIs requesting development of new assays will not be considered.

BACKGROUND

Prevention of type 1 diabetes (T1D) represents a “cure” for those at-risk of developing the disease, and, in fact, will likely represent the most cost-effective approach to a cure and is becoming increasingly important with the rising incidence of the disease. Over the last three to four decades, the incidence of T1D has increased at an annual rate of 3-5% with penetration to low-moderate human leukocyte antigen (HLA) risk groups, suggesting a lowered threshold for its development. In some countries, the largest increase in incidence has occurred in the age group 1-5 years.

Currently, assays of islet autoantibodies (AAb) are the most robust approach to detect risk in relatives of individuals with T1D and aid in predicting progression to T1D in HLA at-risk children. Indeed , the 10-year risk of progression to symptomatic T1D with multiple islet AAbs (insulin, GAD65, IA-2 and ZnT8) is 70%. However, the current practices for AAb screening, including screening for genetic risk in neonates or screening for AAb first-degree or second-degree relatives who are known to have an increased risk, detect only 40% and 15% respectively of individuals who will progress to T1D. Only a relatively small proportion of HLA at-risk children develop T1D.

Therefore, new approaches are required to increase sensitivity and specificity of screening. Existing AAb protocols to predict risk of T1D are also costprohibitive for universal childhood screening.

Efforts are underway to better predict risk of development of autoimmunity and the earliest stages of autoimmunity using metabolomics, microbiome metagenomics, transcriptomics, and T-cell assays.

Furthermore, there are ongoing efforts to integrate and model diverse data (genetic, immunologic, metabolic, age, etc.) to develop composite predictive risk scores that better predict rate of progression.

The development of technologies to improve T1D risk detection in the general population would facilitate recruitment for clinical research focused on identifying environmental triggers and natural history of T1D, along with interventions to prevent T1D.

OBJECTIVES

Expressions of interest are sought from investigators who seek to optimize and/or validate existing platforms for use in predicting risk of T1D, both prior to and after development of AAbs. These assays should meet the following criteria for general population-based screening, which may include newborn or childhood-based screening methods:

a. Selectivity, sensitivity, ease of use

b. High-throughput capacity

c. Low volume needed

d. Low cost

e. Possibility for the assay to be deployed as point-of-care testing

Investigators with ideas or resources that might benefit this initiative should also submit their ideas via an expression of interest.

This EOI will not support the development of new technologies or assays.

ELIGIBILITY

Applicants must hold an M.D., D.M.D., D.V.M., Ph.D., or equivalent academic degree and a faculty position or equivalent at a college, university, medical school, for-profit research based organization or other comparable institution.

Applications may be submitted by domestic or foreign public or private non-profit organizations, such as colleges, universities, hospitals, laboratories, units of state or local governments or eligible agencies of the federal government.

Please note that applications from for-profit entities or industry collaborations with academia may be submitted to this EOI, however, additional information will be requested from for-profitentities if a full application is invited.

There are no citizenship requirements.

MECHANISM

EOIs in response to this announcement can be submitted to the following mechanism:

Strategic Research Agreements (supported by strong feasibility data) for a maximum budget of $200,000 per year for up to 2 years of funding (including 10% indirect costs).

Applications that are not funded in this competition may be resubmitted to other JDRF grant mechanisms according to the deadlines and guidelines described on the JDRF Web site: http://www.jdrf.org/

DEADLINES

-- Expression of Interest: September 22, 2014 (5:00pm, Eastern Time)

-- EOI Notification: October 1, 2014

-- Application Due Date: October 31, 2014 (5:00pm, Eastern Time)

-- Response to Applicants Date:  January 2015

-- Earliest Anticipated Start Date: February 2015

EOI COMPONENTS

Prospective applicants should submit an expression of interest on-line via RMS360 at
https://jdrf.smartsimple.us The EOI template located under the LOI Research Plan tab must be used to
submit.

EOI submissions will undergo expedited review. Applicants will be notified if they have been approved to submit a full application.

JDRF Requests Expressions of Interest for Studies Relevant to the Discovery and Development of Antigen Specific Therapies for Human Type 1 Diabetes

JDRF Requests Expressions of Interest for Studies Relevant to the Discovery and Development of Antigen Specific Therapies for Human Type 1 Diabetes

Key Dates:

August 15, 2014: Expressions of interest (EOI) release date

October 10, 2014: EOI due date

October 31, 2014: EOI decision notification

December 10, 2014: Full application due date (for accepted EOIs)

April 2015: Award notification May 2015: Earliest start date

Purpose of Request

JDRF is soliciting expressions of interest (EOI) for the discovery, development, pre-clinical or pilot clinical testing of novel antigen-specific therapeutic approaches designed to induce durable immunoregulation for human type 1 diabetes (T1D). JDRF is committed to translation of research findings towards clinical results and is most interested in projects that have clinical translation potential.

Background

Immunotherapeutic approaches for preventing or halting T1D have involved both antigen-specific and antigen non-specific interventions. Because T1D results from a failure to maintain immune tolerance to islet antigens/autoantigens, targeting the immune response to these antigens/autoantigens may provide an effective means of preventing and controlling the autoimmune response and avoid the harmful effects associated with non-specific immunosuppression. Clinical data from several independent trials has provided compelling evidence that current immunomodulatory approaches are not optimally effective at preventing T1D or at durably controlling beta cell loss in the recent onset T1D setting. In addition, islet transplantation trials show recurrence of beta cell antigen specific autoreactivity under the cover of immunosuppressive therapy.

Specific Goals of Request

Expressions of interest are sought from investigators interested in discovering and developing, or in evaluating in pre-clinical models or pilot clinical studies, novel antigen-specific therapies for T1D. Such therapies may have application for: 1) the at-risk, immunologically unprimed setting with primary prevention of T1D and/or for the immunologically primed setting with secondary prevention of T1D; 2) for control of autoimmunity in the new onset T1D setting; or 3) in combination with other immunomodulatory therapies or approaches to robustly induce immunoregulation and regenerate beta cells to restore insulin independence in the recent onset and established T1D setting. The clinical translation potential of the investigations should be emphasized. Of interest are also mechanistic studies and biomarker discovery/validation around antigen-specific T1D clinical trials.

Examples of pertinent topics include, but are not limited to:

-- Discovery of novel antigen-specific therapies for T1D

-- Validate and further develop existing antigen-specific approaches to enable and accelerate their clinical translation

-- Dose finding studies, differences in unprimed vs. primed autoimmune responses, optimization of treatment regimens, and in silico modeling

-- Elucidate mechanisms of action of antigen-specific approaches to improve efficacy and refine the therapeutic strategy.

-- Mechanistic studies for ongoing or recently completed antigen-specific clinical trials in T1D

-- Pilot clinical trials of antigen-specific efficacy using a single agent or combination agents as measured by short-term mechanistic endpoints that reflect robust immune-regulation. Please note that JDRF recently released an EOI for Combination Therapies in Type 1 Diabetes. This EOI is not meant as a replication of that EOI, and EOIs that were submitted to that mechanism will not be considered here.

-- Investigators with ideas or resources that might benefit this initiative should also submit their ideas via an expression of interest.

Levels of Funding and Grant Mechanisms:

Applications in response to this announcement can be submitted under one of the following three funding mechanisms:

-- Innovative Grants: up to $110,000 (including 10% indirect costs) for one year only.

-- Strategic Research Agreements (SRAs): up to $250,000/yr (including 10% indirect costs) for up to two years.

For any research projects proposed for 3 years, applicants must contact JDRF to discuss its scientific justification. For any budget that exceeds $250,000/yr, JDRF scientific staff must be contacted with a strong justification, prior to EOI submission. SRAs require quarterly milestones, reporting against those milestones and will receive milestone-based payments.

-- Clinical grants for pilot trials: up to $1,000,000 total costs (including 10% indirect costs) for a maximum of 3 years. For any trials proposed for greater than 3 years or for a larger budget, JDRF scientific staff must be contacted prior to EOI submission. Clinical awards require pre-established milestones and will receive milestone-based payments.

-- For all submissions, proposed budgets should be well-justified and commensurate with the type of study and the research plan.

Verizon Foundation Grant Program

Verizon Foundation Grant Program

The Verizon Foundation’s primary philanthropic focus areas are: Healthcare for children, women and seniors; STEM education for K-12 youth and Energy Management. Grant applications are by invitation only and are reviewed from February 3, 2014 through midnight on October 10, 2014. Please contact your local Verizon Community Relations Manager to learn more.

Healthcare-related Programs

Verizon Foundation is leveraging its technology and resources to improve quality and access for children, women and seniors in rural and urban communities in need. Our main focus is to reduce healthcare disparities, improve access and quality, and enable better chronic disease outcomes through health information technology that educates and empowers patients to self-manage their health.

Improving Access for Children

We use technology to connect children to better healthcare, reducing the impact of chronic disease in our most vulnerable communities. We partner with innovative organizations who aim to reduce the impact and disparities of obesity, diabetes & asthma as chronic conditions through technology to help kids get and stay healthy

Empowering Health for Women

Due to a lack of regular access to care along with other factors, women are frequently diagnosed later with chronic diseases than men, and experience higher fatality rates. That is why we support partnerships that highlight the role technology can play in in increasing access  to care and chronic disease management for underserved women.

Connecting Health for Seniors

We connect healthcare providers, patients and care-givers to create innovative care models, enabling seniors with chronic disease to age in place.  We support the work of our partners nationwide in this endeavor.

Domestic Violence Prevention

We invest in organizations that provide education, prevention, care for victims and empowerment resources.

American College of Cardiology Foundation/Merck Research Fellowships in Cardiovascular Disease and Cardiometabolic Disorders

American College of Cardiology Foundation/Merck Research Fellowships in Cardiovascular Disease and Cardiometabolic Disorders

Deadline: September 22, 2014

Four one-year fellowships will be awarded to support research in adult cardiology. Preference is given to individuals who have had no more than two years of prior full-time experience either in clinical or basic research. Recipients will be expected to pursue a full-time project in clinical research during their year of supported training.

Research Focus: In selecting applications, proposals addressing CVD and Cardiometabolic disorders are encouraged. Included are proposals that address pathophysiology, molecular genetics, metabolic abnormalities leading to cardiovascular disease, hypertension, heart failure, hyperlipidemia, inflammatory mechanisms and new pathways for drug discovery. Proposals focusing on clinically relevant outcomes as a result of the metabolic syndrome, diabetes or obesity are also encouraged. Outcomes studies should focus on clinical/and or systems of care (e.g., quality improvement) interventions, and use outcomes measures of importance to both patients and society, including mortality, significant morbidity or quality of life changes, or economic effects.

Preference for one award will be given to applicants focusing on disparities of care.  Despite increased attention to health disparities at the national, state and community levels, relatively little progress has been made in achieving the vision of eliminating racial and ethnic health disparities.   Since the rates of cardiovascular mortality in the United States are significantly higher for these patients and this is, in fact, the leading cause of death in this demographic, innovative approaches to eliminating these disparities are critical.  In an effort to encourage and support research in this area, proposals will be encouraged that focus on gender, race, geographic, and economic inequalities in cardiovascular care.

Eligibility: Anyone currently in an adult cardiology fellowship training program recognized by the Accreditation Council for Graduate Medical Education or the American Osteopathic Association and who has the recommendation and agreement of his/her training program director and institution.

Selection: Judging will be by the ACCF/Research Fellowship Awards Committee. Criteria for selection will include:

Scientific quality of the project;

Relevance to the research focus as described above;

Qualifications and commitment of the applicant; and

The quality of the training environment.

Successful applicants may pursue this protected year of research either within or following their three years of required training. Preference will be given to individuals who:

Will pursue clinical research training and experience directly involving patients or human subjects.

Have had no more than two years of prior full-time research experience either in clinical or basic research.

Will not hold another major external fellowship or salary award, (e.g., from the National Institutes of Health or the American Heart Association) during the ACCF/Merck funded year.

The Award: Four fellowships in the amount of $70,000 each, to be used for salary support, for one year of research to begin July 1, 2015 and run through June 30, 2016.

Funding Source: The ACCF is grateful to the Merck Company Foundation for their continued financial support for these awards.

For questions, please contact Kristin West at kwest@acc.org or 800-253-4636, ext. 6538.

Call for Visiting Scientist Scholarship Applications 2014: Danish Diabetes Academy

Call for Visiting Scientist Scholarship Applications 2014: Danish Diabetes Academy

Online submission of applications for Visiting Scientist scholarships from the Danish Diabetes Academy is now open with registration deadline September 9, 2014. Researchers at Post Doc level, Assistant Professors or Professors can apply for a scholarship covering expenses related to international scientists visiting a Danish research group for 1-6 months.

Grants

The Danish Diabetes Academy will cover expenses for visits lasting up to 6 months including salary, transportation and rent.

Before you apply

Please note that applicants must:

Have a PhD degree

Have postdoctoral experience

Have an excellent academic record

Be able to document teaching experience

Be able to document intended collaboration with a scientific member of the Danish Diabetes Academy

Be willing to teach/ give lectures and/ or write reviews for the Danish Diabetes Academy

Application deadline

9 September 2014 (12:00 noon)

Further information

Contact: tel. 6541 3960/ e-mail info@danishdiabetesacademy.dk

Requests for Applications: American Diabetes Association and Boehringer Ingelheim Research Award: Chronic Kidney Disease and Renal Insufficiency in the Setting of Diabetes

Requests for Applications: American Diabetes Association and Boehringer Ingelheim Research Award: Chronic Kidney Disease and Renal Insufficiency in the Setting of Diabetes

Deadline: September 15, 2014

This award is designed to support basic, clinical or translational research to better understand the issues surrounding the relationship between diabetes and chronic kidney disease (CKD). Specifically, these grants would support research aimed at 1) understanding the mechanisms underlying the development of renal complications in people with diabetes, and 2) improving the treatment and management of people with chronic kidney disease and diabetes.

Support

Basic science projects will receive a maximum of $345,000 over three years ($115,000 per year, including indirect costs). Clinical or translational science projects will receive a maximum of $660,000 over three years ($220,000 per year, including indirect costs). Indirect costs cannot exceed 15% of requested direct costs; if subcontracts are used, any associated indirect costs must be incorporated into the 15% yearly maximum.
 

Request for Letters of Intent: Glucose Responsive Insulin Discovery and Validation

Request for Letters of Intent: Glucose Responsive Insulin Discovery and Validation

Letter of Interest Deadline: July 11, 2014

JDRF, the world’s leading non-profit organization with the mission to cure, treat and prevent type 1 diabetes
(T1D), invites Letters of Intent (LOI) for the discovery and validation of novel glucose responsive insulin
(GRI) drugs for better treatment of insulin-dependent diabetes mellitus (IDDM) and reducing the burden of daily management of the disease, particularly T1D.

Proposals (supported by strong rationale and/or preliminary data) will be considered for a maximum
budget of up to $500,000* per year for up to 3 years of funding (including 10% indirect costs)

* Applications whose budget and/or timeline exceeds the above specified guidelines, must
obtain JDRF staff approval prior to submitting an LOI

OBJECTIVES

Letters of intent are sought from academic or industry applicants with innovative approaches to discover and
provide validation (proof-of-concept) for insulin delivery proportional to circulating real time levels of blood glucose in animal models of T1D.

Early concepts with limited preliminary results may be considered at reduced scope, budget and timelines
based on strength of hypothesis and feasibility of approach.

Designing glucose-responsive insulins may require a concerted effort from various areas of expertise.
Therefore, applications from a network of investigators and/or collaborations leveraging expertise in protein biochemistry, pharmacology, drug delivery, formulation sciences, bioengineering and other fields, as applicable, will be given a high priority.

Alternately, JDRF Staff may suggest collaborations between two or more applicants based upon complementarity to form a network.

Expected outcomes from project proposals would demonstrate but be not limited to:

-- Insulin release and blood glucose lowering proportional to circulating levels of glucose

-- Improvements in glycemic parameters–glucose tolerance, reduced hypoglycemia, etc.

-- Reversibility of mechanism

-- Safety and tolerability of biomaterials, excipients, etc.

-- Pharmacokinetic and pharmacodynamic measures

-- Evidence of elimination of biomaterials, if any

Applications should contain an analysis of the projected GRI product concept compared to standard-of-
care, including:

-- Target Product Profile and Target Patient Profile

-- Reduced frequency of dosing (such as once-a-day)

-- Reduced need for monitoring blood glucose levels

-- Reduced risk for hypo and hyperglycemia

-- Timelines for development

-- Cost/benefit analysis

-- Competitive landscape

Applicants are encouraged to consult with JDRF Scientific Staff to discuss the alignment of their proposal to this RFA and in developing the projected GRI product concept

Collaborations with industry and/or direct applications by companies are strongly encouraged.

Request for Expressions of Interest: Exploratory Clinical Trials of Non-insulin Adjunct Therapies in Type 1 Diabetes

Request for Expressions of Interest: Exploratory Clinical Trials of Non-insulin Adjunct Therapies in Type 1 Diabetes

Expression of Interest Deadline: July 11, 2014

JDRF, the world’s leading non-profit organization with the mission to cure, treat and prevent type 1 diabetes (T1D), invites Expressions of Interest (EOI) for clinical trials to evaluate non-insulin based adjunct therapies for improved glycemic and overall metabolic control of T1D.

JDRF has an unprecedented opportunity to make progress in the clinical assessment of adjunctive therapies for T1D that move beyond an insulin-centric view of the disease.

At present, several agents–mostly approved T2D therapies such as incretins, SGLT inhibitors, metformin–
are under clinical investigation to assess the benefit: risk profile in T1D. However, a systematic clinical phenotyping of the heterogeneous disease to enable personalized interventions addressing specific dysfunctional pathways or an understanding of the mechanistic pathology is yet to be undertaken. It is our goal to de-convolute the T1D disease complexity such that sub-groups of individuals can be identified and stratified to determine optimal therapeutic regimen of non-insulin adjunct therapies, thus maximizing the benefit: risk ratio for the patients.

JDRF wishes to solicit expressions of interest for clinical trials in established from academic and industry
applicants T1D to test the safety, efficacy, and potential synergies of adjunct therapies that target multiple facets of the disease.

Request for Letters of Intent: Exploratory Clinical Trials for Diabetic Retinopathy

Request for Letters of Intent: Exploratory Clinical Trials for Diabetic Retinopathy

LOI Submission Deadline: .June 20th 2014

JDRF is committed to facilitating the translation of therapies for diabetic retinopathy to individuals with Type 1 Diabetes (T1D). To this end, JDRF is soliciting letters of intent for clinical trials of novel therapies for non-proliferative (NPDR), or proliferative retinopathy (PDR).

Diabetic retinopathy is a sight-threatening complication of diabetes and the largest cause of blindness in the US. Despite recent advances in the treatment of diabetic macular edema, there remains a large unmet clinical need to prevent or reverse vision loss via the treatment of NPDR and PDR.

OBJECTIVES

Letters of intent are sought from investigators with for innovative approaches to arrest or reverse NPDR or
to resolve PDR.

Exploratory and initial proof of concept clinical trials which could provide a strong scientific rationale for larger or pivotal studies will be given highest priority.

Clinical trials must include subjects with T1D; however trials will be considered which also propose enrollment of those with Type 2 Diabetes (T2D). Proof of concept clinical studies may propose use of approved or investigational products based on an excellent scientific rationale. JDRF is particularly interested in clinical trials which propose novel means of subject stratification based on estimated risk of progression of NPDR.

Endpoints of interest include: Change in ETDRS scale; prevention of progress ion or improvement

Visual acuity

Other well-justified measures of visual function

Progression to proliferative diabetic retinopathy

Vision-related quality of life scores

Clinical trials of up to 36 months duration will be considered. Investigators proposing trials exceeding this duration should contact Dr Helen Nickerson to assess whether submission is possible.

Under exceptional circumstances, proposals which also include preclinical studies may be considered if needed to obtain regulatory approval to move forward with the proposed clinical trial. Please contact Dr Helen Nickerson to discuss studies in this area.

Request for Expressions of Interest: Clinical Trials to Preserve Beta Cell Function and Delay Onset of Symptomatic Disease in the At-risk Setting for Type 1 Diabetes (T1D)

Request for Expressions of Interest: Clinical Trials to Preserve Beta Cell Function and Delay Onset of Symptomatic Disease in the At-risk Setting for Type 1 Diabetes (T1D)

Expression of Interest deadline: July 11, 2014

JDRF is soliciting expressions of interest (EOI) for performing secondary prevention clinical trials to preserve beta cell function and delay the onset of symptomatic disease.

These EOIs may include proof-of-concept clinical trials with existing and/or novel therapies and with combination therapies that target different aspects of beta cell dysfunction and loss.

Objectives

Expressions of interest are sought from investigators with access to patient cohorts of individuals with ≥2
T1D autoantibodies to conduct proof-of-concept clinical trials using intermediate trial outcomes/endpoints
to inform larger and longer prevention trials. Intermediate endpoints to be considered include: increasing
HbA1c, onset of dysglycemia, reversal of dysglycemia, change in C-peptide, etc.). Repurposed and/or
novel therapeutics (immune, inflammation, beta cell survival, metabolic, etc.) will be considered.
Combination therapies, used either sequentially or simultaneously, for robust prevention will also be
considered.

Investigators with ideas or resources that might benefit this initiative should also submit their ideas via an
expression of interest.

Mechanistic studies should be built into all trials.

JDRF is concurrently releasing an EOI for Combination Therapies in Type 1 Diabetes.

This EOI is not meant as a replication of that EOI, which focuses on combination therapies for new-onset and established T1D.

Furthermore, EOIs with a focus on primary prevention will not be considered

Mechanism

EOIs in response to this announcement can be submitted to the following mechanism:

Clinical Strategic Research Agreements (supported by strong preliminary data) for a maximum budget of
$1,500,000* per year for up to 3 years of funding (including 10% indirect costs)

Pre-clinical support may be requested only for IND-enabling activities.

* Applications whose budget and/or timeline exceeds the above specified guidelines, must obtain JDRF
staff approval prior to submitting an LOI.

Applications that are not funded in this competition may be resubmitted to other JDRF grant mechanisms
according to the deadlines and guidelines described on the JDRF Web site:
http://www.jdrf.org/

Request for Applications: Identifying and Prioritizing Drug Targets and Combination Therapies to Simultaneously Optimize Regenerative and Survival Responses in the Beta Cell

Request for Applications: Identifying and Prioritizing Drug Targets and Combination Therapies to Simultaneously Optimize Regenerative and Survival Responses in the Beta Cell

Letter of Intent Deadline: July 17, 2014

JDRF invites applications from single investigators or teams of investigators to develop and conduct studies to identify and prioritize pathways, mechanisms, combination approaches and therapies to safely promote human beta cell regeneration while maintaining beta cell survival and function.

This RFA will support performance-driven, milestone-based pre-clinical research programs aimed at identifying and validating drug targets and biologic factors to simultaneously promote human beta cell regeneration and prevent beta cell loss.

It is expected that RFA-sponsored studies may ultimately have implications for treatment of type 1 diabetes and that the data generated may be used to support longer-term drug discovery efforts. Inclusion of studies with human islets/beta cells will be prioritized.

Up to a maximum of $250,000 USD per year including 10% indirect costs for up to 2 years may be requested.

The level of funding will vary depending on the scope and over all objectives of the proposal.

Proposals with significantly higher cost may still be considered at the discretion of JDRF scientists.

Request for Applications: Targeting Islet Cell Plasticity for Regeneration of Beta Cell Function in T1D

Request for Applications: Targeting Islet Cell Plasticity for Regeneration of Beta Cell Function in T1D

Letter of Intent Deadline: July 17, 2014

JDRF invites applications from single investigators or teams of investigators to develop and conduct studies
to identify and prioritize pathways, mechanisms, factors and drug targets to guide therapeutic approaches to drive formation of new beta cells by targeting islet cell plasticity.

This RFA will support performance-driven, milestone-based research programs aimed at identifying and validating mechanisms, pathways and potential drug targets regulating islet cell plasticity.

It is expected that the RFA-sponsored studies may ultimately have implications for treatment of type 1 diabetes and that the data generated may be used to support longer-term efforts aimed at drug discovery and translation.

Proposals that include studies on human islets will be prioritized.

Up to a maximum of $250,000 USD per year including 10% indirect costs for up to 2 years may be requested.

The level of funding will vary depending on the scope and overall objectives of the proposal.

Proposals with significantly higher cost may still be considered at the discretion of JDRF scientists.

Request for Applications: JDRF Encapsulation Consortium: Developing and Testing Novel Encapsulation Technologies

Request for Applications: JDRF Encapsulation Consortium: Developing and Testing Novel Encapsulation Technologies

Full applications should be submitted no later than August 1, 2014 at 5 p.m. EST via RMS360 (http://jdrf.smartsimple.us).

One of JDRF’s therapeutic goals is to restore beta cell function in type 1 diabetes (T1D) by replacement/transplantation of beta cells/islets.

Pancreatic islet transplantation has been efficacious in selected patients in improving metabolic control and quality of life, and in preventing severe hypoglycemia in patients with medically unstable T1D. Despite improvements in cadaveric pancreas procurement, islet isolation, and islet purification, major scientific and technical challenges remain that must be addressed before beta cell replacement will be widely incorporated into the clinical management of established T1D; examples include serious side effects from chronic immunosuppression, islet sensitivity to certain immunosuppressants, the insufficient human islet supply from cadaveric pancreata, and the desire for an alternative transplantation site. JDRF’s role is to enable the scientific community to address these challenges with the ultimate goal of developing safe and effective transplantation approaches available to large numbers of individuals with T1D.

Each project may request up to total $350,000 USD per year (including 10 % indirect costs), for up to three years.

Innovative pilot and feasibility studies without significant preliminary data may request up to total $150,000
USD per year for one year (including 10 % indirect costs).

Indirect costs may not exceed 10% of the direct costs.

Applicants are strongly advised to consult with the JDRF Programmatic Contact by July 1, 2014 to discuss the responsiveness of their proposal to this program. 

Call for Nominations: American Diabetes Association Richard R. Rubin Award

Call for Nominations: American Diabetes Association Richard R. Rubin Award

Formerly the Behavioral Medicine & Psychology Interest Group Lectureship for Distinguished Contributions, the Richard R. Rubin Award Lecture is given in memory of Richard R. Rubin, PhD, CDE, a long time Association volunteer, who served as President, Health Care and Education, and chair of the Council on Behavioral Medicine & Psychology, and received numerous professional and service awards. Specifically, the Richard R. Rubin Award recognizes a behavioral researcher who has made outstanding and/or innovations contributions in the study and understanding of the behavioral aspects of diabetes.

Criteria for Selection: Principal criteria for selection: To recognize a behavioral researcher who has made outstanding and/or innovative contributions in the study and understanding of behavioral aspects of diabetes. Nominee will be recognized for national and/or international contributions to the field of behavioral medicine in diabetes Nominee must be an active American Diabetes Association member. No specific degree requirements, but a clinical/research focus in behavioral health is strongly preferred Both U.S. and non-U.S. residents are eligible for Award. Contributions as an American Diabetes Association volunteer and to the broader diabetes community may also be taken into consideration.

Lecture/Publication of Lecture: Recipient will deliver the Richard R. Rubin Award Lecture at the 75th Scientific Sessions in Boston, Massachusetts; June 5-9, 2015. Offered the opportunity to publish lecture in an American Diabetes Association scientific journal.

Honorarium/Travel/Registration: The recipient receives a $1,000 honorarium. Award includes complimentary hotel accommodations for up to 3-nights within an Association hotel block and one round-trip coach airfare. Includes one complimentary registration to Scientific Sessions.

2015 Nomination/Submission Process: 2015 Nominations must be submitted using the new electronic nomination form. All submissions must be received on or before 8pm ET, July 25, 2014. Nominations are accepted from any professional member of the American Diabetes Association. Nominations from the membership of the Behavioral Medicine & Psychology Interest Group in particular are encouraged and will be solicited.

All Richard R. Rubin Award nominations must have the following documents uploaded as one .pdf file:

-- Letter of nomination (no more than 400 words), signed by no more than 3 individuals, will be accepted. Letter of nomination should address criteria for selection.

-- Nominee’s biography

-- Please include nominee’s CV with career and publication highlights, as well as documentation of teaching and mentorship must also be included.

Questions? Contact Mary Merkin, Senior Manager, Scientific and Medical by email at mmerkin@diabetes.org or call 703-549-1500, ext 1371.

Selection: The recipient is chosen by a selection committee comprised of the Chair of the Behavioral Medicine and Psychology Section and the past 3 recipients of the Award. The selection committee will review and discuss all nominations and select the recipient on the basis of outstanding achievement or innovative contributions that have led to advances in the study and understanding of behavioral aspects of living with diabetes and its prevention and treatment. The selection process is reviewed and supported by the National Medicine, Science and Health Care Awards Committee. The nominee is approved by the Executive Committee of the American Diabetes Association.

Call for Nominations: American Diabetes Association Roger E. Pecoraro Award

Call for Nominations: American Diabetes Association Roger E. Pecoraro Award

Given in memory of Roger E. Pecoraro, MD, a pioneer in research on the causes and prevention of foot ulcers and amputations in diabetes, The Roger E. Pecoraro Lectureship Award recognizes a researcher who has made scientific contributions and demonstrates an untiring commitment to improving the understanding of detection, treatment and prevention of diabetic foot complications.

Criteria for Selection: Principal criteria for selection: recognizing significant and/or innovating scientific achievement in improving the understanding of detection, treatment and prevention of diabetic foot complications Nominee will be recognized for national and/or international contributions to the field of research on diabetes complications Nominee must be an active American Diabetes Association member. Impact as a teacher and mentor will also be taken into consideration. Eligible candidates hold an doctorate level clinical or research degree (MD, DO, DPM, PhD) Both US and non-US residents are eligible Contributions as an American Diabetes Association volunteer and to the broader diabetes community may also be taken into consideration.

Lecture/Publication of Lecture: Recipient will deliver the Roger Pecoraro Award Lecture at the 75th Scientific Sessions in Boston, Massachusetts; June 5-9, 2015. Offered the opportunity to publish lecture in an American Diabetes Association scientific journal.

Honorarium/Travel/Registration: The recipient receives a $1,000 honorarium. Award includes complimentary hotel accommodations for up to 3-nights within an Association hotel block and one round-trip coach airfare. Includes one complimentary registration to Scientific Sessions.

2015 Nomination/Submission Process: 2015 Nominations must be submitted using the new electronic nomination form. All submissions must be received on or before 8pm ET, July 25, 2014. Nominations are accepted from any professional member of the American Diabetes Association. Nominations from the membership of the Interest Group in Foot Care are encouraged and will be solicited.

All Roger Pecoraro Award nominations must have the following documents uploaded as one .pdf file:

-- Letter of nomination (no more than 400 words), signed by no more than 3 individuals, will be accepted. Letter of nomination should address criteria for selection.

-- Nominee’s biography

-- Please include nominee’s CV with career and publication highlights, as well as documentation of teaching and mentorship must also be included.

Questions? Contact Mary Merkin, Senior Manager, Scientific and Medical by email at mmerkin@diabetes.org or call 703-549-1500, ext 1371.

Selection: Nominations are reviewed and scored by selected experts and past chairs from the Council on Foot Care appointed by the current chair of the Interest Group on Foot Care. The selection process is reviewed and supported by the National Medicine, Science and Health Care Awards Committee. The nominee is approved by the Executive Committee of the American Diabetes Association.

Call for Nominations: American Diabetes Association Norbert Freinkel Award

Call for Nominations: American Diabetes Association Norbert Freinkel Award

This lecture award is given in memory of Norbert Freinkel, a dedicated and insightful investigator, as well as gifted writer to honor a researcher who has made outstanding contributions to the field of diabetes and pregnancy.

Criteria for Selection: In recognition of outstanding contributions (including scientific publications and presentations) to the understanding and treatment of diabetes and pregnancy. Nominee will be recognized for national and/or international contributions to the field of diabetes in pregnancy. Nominee must be an active American Diabetes Association member. MD or PhD degree or equivalent. Both U.S. and non-U.S. residents are eligible for Award. Contributions as an American Diabetes Association volunteer and to the broader diabetes community may also be taken into consideration.

Lecture/Publication of Lecture: Recipient will deliver the Norbert Freinkel Award Lecture at the 75th Scientific Sessions in Boston, Massachusetts; June 5-9, 2015. Offered the opportunity to publish lecture in an American Diabetes Association scientific journal.

Honorarium/Travel/Registration: The recipient receives a $1,000 honorarium. Award includes complimentary hotel accommodations for up to 3-nights within an Association hotel block and one round-trip coach airfare. Includes one complimentary registration to Scientific Sessions.

2015 Nomination/Submission Process: 2015 Nominations must be submitted using the new electronic nomination form. Submissions must be received on or before 8pm ET, July 25, 2014. Nominations are accepted from any professional member of the American Diabetes Association. Nominations from the membership of the Pregnancy & Reproductive Health Interest Group in particular are encouraged and will be solicited.

All Frienkel Award nominations must have the following documents uploaded as one .pdf file:

-- Letter of nomination (no more than 400 words), signed by no more than 3 individuals, will be accepted. Letter of nomination should address criteria for selection.

-- Nominee’s biography

-- Please include nominee’s CV with career and publication highlights, as well as documentation of teaching and mentorship must also be included.

Questions? Contact Mary Merkin, Senior Manager, Scientific and Medical, by email at mmerkin@diabetes.org or call 703-549-1500, ext 1371.

Selection:

Nominations are reviewed and scored by selected experts from the Pregnancy & Reproductive Health Interest Group and past award recipients of the Freinkel Award.

The selection process is reviewed and supported by the National Medicine, Science and Health Care Awards Committee. The nominee is approved by the Executive Committee of the American Diabetes Association.

Call for Nominations: American Diabetes Association Edwin Bierman Award

Call for Nominations: American Diabetes Association Edwin Bierman Award

This lecture is awarded in honor of the memory of Edwin L. Bierman, MD. Dr. Bierman was an exemplary scientist, mentor and leader in the field of diabetes, obesity, hyperlipidemia and atherosclerosis.

The award and lecture recognizes a leading scientist in the field of macrovascular complications and contributing risk factors in diabetes. Dr. Bierman is most notably remembered for his work on the physiologic and nutritional regulation of lipoprotein metabolism and the nature of lipid and lipoprotein disorders particularly in obesity and diabetes, and especially as these relate to atherosclerosis. He was also a pioneer using human cultured cells to study atherosclerosis. Dr. Bierman founded one of the leading journals in the area of atherosclerosis, namely Arteriosclerosis, Thrombosis, and Vascular Biology, and had a major impact on our understanding of diabetes and macrovascular disease.

Criteria for Selection: To recognize a leading scientist who has made outstanding contributions in the field of macrovascular complications and the management and treatment of diabetes. Nominee will be recognized for national and/or international contributions to the field of research on diabetes complications. Nominee must be an active American Diabetes Association member. MD or PhD degree or equivalent. Both US and non-US residents are eligible for Award. Contributions as an American Diabetes Association volunteer and to the broader diabetes community may also be taken into consideration.

Lecture/Publication of Lecture: Recipient will deliver the Edwin Bierman Award Lecture at the 75th Scientific Sessions in Boston, Massachusetts; June 5-9, 2015. Offered the opportunity to publish lecture in an American Diabetes Association scientific journal.

Honorarium/Travel/Registration: The recipient receives a $1,000 honorarium. Award includes complimentary hotel accommodations for up to 3-nights within an Association hotel block and one round-trip coach airfare. Includes one complimentary registration to Scientific Sessions.

2015 Nomination/Submission Process: 2015 Nominations must be submitted using the new electronic nomination form. All submissions must be received on or before 8pm ET, July 25, 2014. Nominations are accepted from any professional member of the American Diabetes Association. Nominations from the membership of the Complications Interest Group in particular are encouraged to submit nominations.

All Edwin Bierman Award nominations must have the following documents uploaded as one .pdf file:

-- Letter of nomination (no more than 400 words), signed by no more than 3 individuals, will be accepted. Letter of nomination should address criteria for selection.

-- Nominee’s biography

-- Please include nominee’s CV with career and publication highlights, as well as documentation of teaching and mentorship must also be included.

Questions? Contact Mary Merkin, Senior Manager, Scientific and Medical, by email at mmerkin@diabetes.org or call 703-549-1500, ext 1371.

Selection: The recipient is chosen by a selection committee comprised of the chair current chair of the Complications Interest Group and former Bierman Award recipients. The selection committee will review and discuss all nominations and select the recipient on the basis of outstanding contributions to the field of macrovascular complications in the knowledge, management and treatment of diabetes. The selection process is reviewed and supported by the National Medicine, Science and Health Care Awards Committee. The nominee is approved by the Executive Committee of the American Diabetes Association.

Pages